Zevra Therapeutics assumed with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald assumed coverage of Zevra Therapeutics (ZVRA) with an Overweight rating and $25 price target Zevra is a rare disease, commercial-stage biotechnology company with two approved drugs: MIPLYFFA for Niemann-Pick Disease Type C and OLPRUVA for Urea Cycle Disorders, the analyst tells investors in a research note. The firm’s bullish thesis and bulk of its valuation stems from MIPLYFFA, with data demonstrating that MIPLYFFA + miglustat saw halting of disease/slight benefit, corresponding to disease-modification, Cantor says.